阿托伐他汀联合曲美他嗪治疗冠心病的临床效果分析

Clinical Effect of Atorvastatin Combined with Trimetazidine in the Treatment of Coronary Heart Disease

目的:探讨冠心病患者应用阿托伐他汀联合曲美他嗪治疗的效果。方法:选取2020年7月—2021年7月赤壁市蒲纺医院收治的80例冠心病患者,以抽签法将其分为观察组和对照组,各40例。对照组施以阿托伐他汀治疗,观察组以对照组为基础加用曲美他嗪治疗。比较两组治疗前后心功能、氧化应激及炎症因子水平。结果:治疗前,两组心功能、氧化应激及炎症因子水平比较,差异无统计学意义(P>0.05);观察组治疗后左室射血分数(left ventricular ejection fraction,LVEF)高于对照组,左室收缩末期内径(left ventricular end systolic diameter,LVESD)、左室舒张末期内径(left ventricular end diastolic dimension,LVEDD)低于对照组,差异有统计学意义(P<0.05);治疗后,两组超氧化物歧化酶(superoxide dismutase,SOD)、丙二醇(MDA)较治疗前均改善,观察组SOD高于对照组,MDA低于对照组,差异有统计学意义(P<0.05);治疗后,两组C反应蛋白(C-reactive protein,CRP)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白细胞介素-6(interleukin 6,IL-6)较治疗前均降低,且观察组低于对照组,差异有统计学意义(P<0.05)。结论:阿托伐他汀联合曲美他嗪应用于冠心病患者中,可调节心功能,改善氧化应激水平,并降低炎症因子水平。

Objective:To analyze the effect of Atorvastatin combined with Trimetazidine in the treatment of patients with coronary heart disease.Method:A total of 80 patients with coronary heart disease who treated in Chibi City Pufang Hospital from July 2020 to July 2021 were selected and divided into the observation group and the control group according to the grouping mode of lottery method,40 cases in each group.The control group was treated with Atorvastatin,and the observation group was treated with Trimetazidine on the based of the control group.The cardiac function,oxidative stress and inflammatory factors were compared between two groups before and after treatment.Result:Before treatment,there were no significant differences in the levels of cardiac function,oxidative stress and inflammatory factors between two groups(P>0.05);the left ventricular ejection fraction(LVEF)in the observation group after treatment was higher than that in the control group,while the left ventricular end systolic diameter(LVESD)and left ventricular end diastolic dimension(LVEDD)were lower than those in the control group,the differences were statistically significant(P<0.05);after treatment,the superoxide dismutase(SOD)and propylene glycol(MDA)in two groups were improved compared with those before treatment,the SOD in the observation group was higher than that in the control group,while MDA was lower than that in the control group,the differences were statistically significant(P<0.05);after treatment,the C-reactive protein(CRP),tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)in two group were decreased compared with those before treatment,and which in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).Conclusion:Atorvastatin combined with Trimetazidine in patients with coronary heart disease can regulate cardiac function,improve the level of oxidative stress,and decrease the levels of inflammatory factors.